Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TCRX
- Price
- 1.24
- Stock movement up
- +0.11 (9.73%)
- Company name
- Tscan Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 60.88M
- Ent value
- 46.70M
- Price/Sales
- 6.50
- Price/Book
- 0.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -82.85%
- 3 year return
- -23.32%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TCRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia. See why I rate TCRX stock as a buy.
February 10, 2025
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.50 |
| Price to Book | 0.27 |
| EV to Sales | 4.99 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.09M |
| EPS (TTM) | -0.94 |
| FCF per share (TTM) | -0.93 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.36M |
| Gross profit (TTM) | 5.71M |
| Operating income (TTM) | -119.47M |
| Net income (TTM) | -111.30M |
| EPS (TTM) | -0.94 |
| EPS (1y forward) | -1.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 61.01% |
| Operating margin (TTM) | -1276.07% |
| Profit margin (TTM) | -1188.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 133.12M |
| Net receivables | 0.00 |
| Total current assets | 274.08M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 348.03M |
| Accounts payable | 3.65M |
| Short/Current long term debt | 90.36M |
| Total current liabilities | 28.66M |
| Total liabilities | 118.94M |
| Shareholder's equity | 229.09M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -107.18M |
| Capital expenditures (TTM) | 3.41M |
| Free cash flow (TTM) | -110.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -48.59% |
| Return on Assets | -31.98% |
| Return on Invested Capital | -47.77% |
| Cash Return on Invested Capital | -47.46% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.17 |
| Daily high | 1.24 |
| Daily low | 1.14 |
| Daily Volume | 347K |
| All-time high | 13.48 |
| 1y analyst estimate | 12.14 |
| Beta | 0.78 |
| EPS (TTM) | -0.94 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| TCRX | S&P500 | |
| Current price drop from All-time high | -90.80% | -12.89% |
| Highest price drop | -91.84% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -66.38% | -11.07% |
| Avg time to new high | 134 days | 12 days |
| Max time to new high | 917 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
60.88M
Marketcap category
Small-cap
Description
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Employees
188
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page